Biomarkers, primer sets and detection kits for predicting clinical outcomes in stage II and III colorectal cancer

By using biomarker combinations such as IRS2, TRIM25, MYBL2, etc., RS scores were calculated, and the problem of inaccurate prognosis assessment of colorectal cancer in the prior art was solved, and accurate distinction and personalized treatment plans were achieved in patients with colorectal cancer. Provided.

CN118406766BActive Publication Date: 2024-11-01TIANJIN YUNJIAN MEDICAL TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410873864.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-01
Estimated Expiration
2044-07-02

AI Technical Summary

Technical Problem

The existing prognostic assessment methods for colorectal cancer lack effective biomarkers, which leads to the inability to accurately distinguish high-risk and low-risk patients, which in turn affects the formulation of chemotherapy regimens.

Method used

Using biomarkers such as IRS2, TRIM25, MYBL2, KRT6B, FMNL2, NAT1, FAP, MYC, INHBA, etc., the RS score was calculated to distinguish the risk of recurrence in patients with colorectal cancer by PCR detection and circulating threshold score.

Benefits of technology

Effectively distinguish the risk of recurrence of colorectal cancer and provide more personalized treatment plans, which significantly improves the accuracy and effectiveness of treatment for patients with stage II and III colorectal cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118406766B_ABST
    Figure CN118406766B_ABST
Patent Text Reader

Abstract

The embodiment of the present invention discloses biomarkers, primer sets and detection kits for predicting the clinical results of the prognosis of stage II and stage III colorectal cancer; the biomarkers are IRS2, TRIM25, MYBL2, KRT6B, FMNL2, NAT1, FAP, MYC and INHBA. The RS score of colorectal cancer can be obtained by detecting the level of colorectal cancer biomarkers, which can effectively distinguish the high and low risks of colorectal cancer recurrence; the formula for stage II colorectal cancer is (IRS2-TRIM25) + (IRS2-MYBL2) + (KRT6B-FMNL2) + (INHBA-MYC); the formula for stage III colorectal cancer is (IRS2-TRIM25) + (KRT6B-NAT1) + (FAP-MYC) + (INHBA-MYC), and a more personalized and effective treatment plan is provided for patients according to the scoring results.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biological detection technology, and specifically relates to a biomarker, a primer set and a detection kit for predicting the prognosis clinical results of stage II and stage III colorectal cancer. Background Art

[0002] The ability to predict cancer treatment outcomes under standard care could help physicians decide on potential adjuvant therapy. For example, if a patient has a poor prognosis for treatment outcome, more aggressive adjuvant therapy might be given. Currently, most diagnostic tests or clinical indications used in practice are not quantitative, such as immunohistochemistry (ICH), which often produces different results in different laboratories, which may be due to nonstandard reagents and subjective interpretation of the results.

[0003] Being able to stratify patients with stage II and III colorectal cancer (CRC) based on risk of recurrence and clinical outcome after initial treatment would allow clinicians to tailor chemotherapy regimens that are best suited for specific patients. Currently, adjuvant chemotherapy is the standard of care for patients with stage III colorectal cancer, but clinical data are lacking to identify low-risk stage III colorectal cancer patients who may not require oxaliplatin-based chemotherapy. For patients with stage II colorectal cancer, adjuvant chemotherapy is recommended only for high-risk patients.

[0004] However, current criteria for defining high-risk patient characteristics are inadequate. For stage II colorectal cancer, known prognostic factors leading to poor prognosis include tumor invasion depth (T stage), lymph node number, mismatch repair (MMR) status, tumor grade, and lymphatic and vascular invasion (LVI) score, but only T stage, lymph node number, and MMR status have a large amount of clinical evidence to support their limited use.

[0005] The company (Exact Sciences) has developed a 12-gene recurrence score test, the OncotypeDX Colon Recurrence Score Test, which is based on a scoring system for quantitative polymerase chain reaction qPCR results and can quantitatively display the possibility of recurrence risk. However, when using single covariate Cox regression, the hazard ratio HR for the recurrence rate score per interquartile range IQR was only 1.38, while when using multi-covariate Cox regression, the hazard ratio HR was 1.43. The Oncotype Dx recurrence score for colorectal cancer is worse than the current clinical predictive indicators T stage and MMR status, and is close to the number of lymph nodes examined. Therefore, the clinical application of the 12-gene recurrence score test in colorectal cancer is very low and is not often used in clinical practice. Summary of the invention

[0006] In view of this, on the one hand, some embodiments disclose biomarkers for predicting the prognosis and clinical outcomes of stage II and stage III colorectal cancer, wherein the biomarkers are IRS2, TRIM25, MYBL2, KRT6B, FMNL2, NAT1, FAP, MYC, and INHBA.

[0007] Further, some embodiments disclose biomarkers for predicting the prognosis and clinical outcomes of stage II and stage III colorectal cancer, and the biomarkers used for assessing the risk of recurrence in patients with stage II colorectal cancer are a combination of IRS2-TRIM25, IRS2-MYBL2, KRT6B-FMNL2 and INHBA-MYC.

[0008] Some embodiments disclose biomarkers for predicting the prognosis and clinical outcomes of stage II and stage III colorectal cancer, characterized in that the biomarkers used for assessing the risk of recurrence in patients with stage III colorectal cancer are a combination of IRS2-TRIM25, KRT6B-NAT1, FAP-MYC and INHBA-MYC.

[0009] On the other hand, some embodiments disclose primer sets for PCR detection of biomarkers for predicting the prognosis and clinical outcomes of stage II and stage III colorectal cancer, including an IRS2 primer set, a TRIM25 primer set, a KRT6B primer set, a MYBL2 primer set, a FMNL2 primer set, a NAT1 primer set, a FAP primer set, a MYC primer set, and an INHBA primer set, and the sequences of the above primer sets are listed in SEQ ID No. 1 to 18, respectively.

[0010] On the other hand, some embodiments disclose a detection kit for predicting the prognosis clinical outcome of stage II and stage III colorectal cancer, comprising a primer set for PCR detection of biomarkers for predicting the prognosis clinical outcome of stage II and stage III colorectal cancer.

[0011] Furthermore, some embodiments disclose a detection kit for predicting the prognosis and clinical outcomes of stage II and stage III colorectal cancer, wherein the biomarkers used for assessing the risk of recurrence in patients with stage II colorectal cancer are a combination of IRS2-TRIM25, IRS2-MYBL2, KRT6B-FMNL2 and INHBA-MYC.

[0012] Some embodiments disclose a detection kit for predicting the prognosis and clinical outcomes of stage II and stage III colorectal cancer, wherein the biomarkers used for assessing the risk of recurrence in patients with stage III colorectal cancer are a combination of IRS2-TRIM25, KRT6B-NAT1, FAP-MYC and INHBA-MYC.

[0013] Furthermore, some embodiments disclose a detection kit for predicting the prognosis clinical outcome of stage II and stage III colorectal cancer, which is used to measure the cycle threshold of biomarkers in tissue samples of colorectal cancer patients.

[0014] In some embodiments, the detection kit for predicting the prognosis of stage II and stage III colorectal cancer clinical outcomes is disclosed, and the cycle threshold of the biomarker is converted into the colorectal cancer RS ​​score.

[0015] Some embodiments disclose a detection kit for predicting the clinical outcome of the prognosis of stage II and stage III colorectal cancer. The formula for stage II colorectal cancer is (IRS2-TRIM25) + (IRS2-MYBL2) + (KRT6B-FMNL2) + (INHBA-MYC). If the RS score of colorectal cancer is higher than the critical value of 2.589, it indicates that patients with stage II colorectal cancer are at high risk of poor prognosis after initial treatment; the formula for stage III colorectal cancer is (IRS2-TRIM25) + (KRT6B-NAT1) + (FAP-MYC) + (INHBA-MYC). If the RS score of colorectal cancer is higher than the critical value of -0.1355, it indicates that patients with stage III colorectal cancer have a higher risk of colorectal cancer recurrence.

[0016] The embodiments of the present invention disclose a biomarker group, a primer group, and a detection kit for predicting the clinical outcomes of the prognosis of stage II and stage III colorectal cancer. By detecting the levels of colorectal cancer biomarkers, a colorectal cancer RS ​​score can be obtained, which can effectively distinguish the high and low risks of colorectal cancer recurrence; it can better evaluate the treatment risk and prognosis of colorectal cancer patients, thereby providing patients with more personalized and effective treatment plans. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 , Kaplan-Meier estimates of the three-year recurrence rate for patients undergoing surgery alone (full cohort of patients);

[0018] Figure 2 , Kaplan-Meier estimates of the three-year recurrence rate for patients undergoing surgery alone (stage II patients);

[0019] Figure 3 , Kaplan-Meier estimates of the three-year recurrence rate for patients undergoing surgery alone (stage III patients);

[0020] Figure 4 , recurrence-free interval by mProbe recurrence score (RS) group (all patients);

[0021] Figure 5 , recurrence-free interval in the mProbe recurrence score (RS) group (stage II patients);

[0022] Figure 6 , recurrence-free interval in the mProbe recurrence score (RS) group (stage IIIA / B patients);

[0023] Figure 7 , Kaplan-Meier estimates of three-year recurrence rates by risk group for patients undergoing surgery alone (full cohort of patients) using Oncotype Dx and the scoring system;

[0024] Figure 8 , Kaplan-Meier estimates of three-year recurrence rates in risk groups of patients undergoing surgery alone (stage II patients) by using Oncotype Dx and the scoring system;

[0025] Fig. 9 , Kaplan-Meier estimates of three-year recurrence rates in risk groups of patients undergoing surgery alone (stage III colon cancer patients) by using Oncotype Dx and the scoring system;

[0026] Fig.10 , recurrence-free interval according to Oncotype Dx recurrence score (RS) groups (all patients);

[0027] Fig.11 , recurrence-free interval according to Oncotype Dx recurrence score (RS) groups (stage II patients);

[0028] Fig.12 , recurrence-free interval according to Oncotype Dx Recurrence Score (RS) groups (stage IIIA / B patients). DETAILED DESCRIPTION

[0029] The word "embodiment" used herein as an "exemplary" does not necessarily mean that any embodiment described is superior or better than other embodiments. Performance index tests in the embodiments of the present invention are performed using conventional test methods in the art unless otherwise specified. It should be understood that the terms described in the embodiments of the present invention are only used to describe specific implementation methods and are not intended to limit the contents disclosed in the embodiments of the present invention.

[0030] The terms "substantially" and "approximately" used herein are used to describe small fluctuations. For example, they can refer to less than or equal to ±5%, such as less than or equal to ±2%, such as less than or equal to ±1%, such as less than or equal to ±0.5%, such as less than or equal to ±0.2%, such as less than or equal to ±0.1%, such as less than or equal to ±0.05%. The numerical data represented or presented in the range format herein are used only for convenience and brevity, and therefore should be flexibly interpreted as not only including the values ​​clearly listed as the limits of the range, but also including all independent values ​​or sub-ranges contained in the range. For example, the numerical range of "1-5%" should be interpreted as including not only the clearly listed values ​​of 1% to 5%, but also the independent values ​​and sub-ranges within the range shown. Therefore, independent values ​​such as 2%, 3.5% and 4% and sub-ranges such as 1%-3%, 2%-4% and 3%-5% are included in this numerical range. This principle also applies to the range of only one numerical value. In addition, such an explanation applies regardless of the width of the range or the characteristics. In this document, including in the claims, transitional words such as "comprises," "includes," "with," "having," "containing," "involving," "accommodating," etc. are understood to be open-ended, i.e., meaning "including but not limited to." Only the transitional words "consisting of" and "composed of" are closed transitional words.

[0031] In order to better illustrate the present invention, numerous specific details are provided in the specific examples below. It should be understood by those skilled in the art that the present invention can be implemented without certain specific details. In the embodiments, some methods, means, instruments, equipment, etc. well known to those skilled in the art are not described in detail in order to highlight the gist of the present invention.

[0032] Under the premise of no conflict, the technical features disclosed in the embodiments of the present invention may be arbitrarily combined, and the resulting technical solutions belong to the contents disclosed in the embodiments of the present invention.

[0033] The present invention discloses colorectal cancer (CRC) biomarkers, CRC biomarker combinations, and methods for obtaining CRC risk assessment biomarker level representations of samples. These combinations and methods play a role in assessing the risk of stage II and stage III treatment outcomes and the likelihood of colorectal cancer recurrence. At the same time, systems, devices, and kits for implementing the above methods are also provided. The details of the combinations and methods fully described below will become apparent to those skilled in the art who understand the technical solutions disclosed herein.

[0034] It should be understood that the disclosure of the embodiments of the present invention is not limited to the specific methods or combinations described, as these may vary. At the same time, it should be understood that the terms used herein are only for describing specific embodiments and are not intended to be limiting.

[0035] Unless otherwise defined, all technical and scientific terms used herein are to be interpreted as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and preferred methods and materials will now be described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials associated with the cited publications. If there is a conflict, it should be understood that the content disclosed herein supersedes any disclosure of the incorporated publication.

[0036] After the disclosure of the present invention document, it is obvious to those with professional skills in the technical field that each specific embodiment described and illustrated herein has independent components and features that can be easily separated or combined from the features of other embodiments, and this will not deviate from the scope or inventive concept of the present invention. Any method mentioned can be executed in the order of events mentioned, or in any other logically possible order.

[0037] As used herein, "colorectal cancer" or "CRC" refers to an abnormal, uncontrolled growth in the colon or rectum. It is also known as colon cancer, and the colon is the large intestine or large bowel. The rectum is the passage that connects the colon to the anus. So-called "risk assessment for colorectal cancer," or "determining CRC risk as one of the clinical signs," generally means providing a CRC risk as an additional clinical sign, for example, determining a patient's risk of CRC recurrence after initial treatment; a risk assessment for the course of disease progression and / or disease outcomes, such as five-year overall survival or progression-free survival.

[0038] The following examples are provided to provide a person skilled in the art with a description of how to make and use the technical solutions of the present invention, and are not intended to limit the scope of the invention, nor are they intended to indicate that the following experiments are all or only experiments. The accuracy of the numbers used (e.g., quantities, temperatures, etc.) is ensured in the text, but some experimental errors and deviations should be taken into account.

[0039] In some embodiments, a method for determining the expression level of a colorectal cancer biomarker in a subject comprises:

[0040] a. Evaluate a set of colorectal cancer biomarkers in a sample to determine the expression level of each colorectal cancer biomarker in the sample, wherein the sample includes surgically removed tumor tissue or FFPE tissue of a colorectal cancer patient; the colorectal cancer biomarkers are IRS2, TRIM25, MYBL2, KRT6B, FMNL2, NAT1, FAP, MYC, and INHBA; the RNA or DNA level of the biomarker can usually be obtained by detecting the nucleic acid sequence; the expression level of the biomarker can usually be expressed by a cycle threshold, i.e., a Ct value; the cycle threshold can usually be expressed as an absolute concentration or multiple of the median (i.e., MoM);

[0041] b. Obtaining the colorectal cancer biomarker level based on the expression level of each colorectal cancer biomarker in the combination.

[0042] Typically, the biomarker expression levels of sample tissue / sample FFPE tissue are correlated with the risk of colorectal cancer recurrence in tumor tissue. A qPCR detection system, such as ABI QuantStudio 4, can be used to accurately measure the expression levels of biomarkers and derive a colorectal cancer risk score. The risk score can be used to distinguish high-risk patients from low-risk patients.

[0043] In certain embodiments, the primers used for qPCR detection of biomarker expression levels include IRS2 primer set, TRIM25 primer set, KRT6B primer set, MYBL2 primer set, FMNL2 primer set, NAT1 primer set, FAP primer set, MYC primer set, and INHBA primer set; for genes associated with colorectal cancer recurrence that appear in primary tumor tissues, a quantitative PCR system is used to accurately measure tissue biomarker gene expression, such as copy number, to derive a recurrence score RS, and distinguish high-risk and low-risk patients with stage II and stage III CRC. PCR systems include, for example, Applied Biosystem QuantStudio, 7500 Real-Time PCR system, or Bio-Rad CFX system. Among them, the IRS2 primer set refers to a specific primer pair for the IRS2 gene, which can convert the mRNA of the IRS2 gene into cDNA in the qPCR analysis, and then amplify it, and perform qPCR detection and analysis.

[0044] The gene names and the sequences of the corresponding primer sets are as follows:

[0045] Gene name: IRS2;

[0046] SEQ ID No.1: CCTACGCCAGCATTGACTT;

[0047] SEQ ID No.2: TGACATCCTGGTGATAAAGCC;

[0048] Gene name: TRIM25;

[0049] SEQ ID No.3: GGATGAGTTCGAGTTTCTGGAG;

[0050] SEQ ID No.4: GCCTTTTATCAGCTTGTGGTTC;

[0051] Gene name: MYBL2;

[0052] SEQ ID No.5: GCCGAGATCGCCAAGATG;

[0053] SEQ ID No.6: CTTTTGATGGTAGAGTTCCAGTGATTC;

[0054] Gene name: KRT6B;

[0055] SEQ ID No.7: GCCCTCACTTTTCTTCTCATCA;

[0056] SEQ ID No.8: CATGTCTGAGTGCTGATAACTGT;

[0057] Gene name: FNML2;

[0058] SEQ ID No.9: AGAATGAAGCCATGTCCAAGA;

[0059] SEQ ID No.10: GTGTGAACTTGAGTATTTGCATCT;

[0060] Gene name: NAT1;

[0061] SEQ ID No.11: AACTGAAGATCAACCTACTTTCAAC;

[0062] SEQ ID No.12: GTTTCCAAGTCCAATTTGTTCCTA;

[0063] Gene name: FAP;

[0064] SEQ ID No.13: CTGACCAGAACCACGGCT;

[0065] SEQ ID No.14: GGAAGTGGGTCATGTGGG;

[0066] Gene name: MYC;

[0067] SEQ ID No.15:TCCCTCCACTCGGAAGGACTA;

[0068] SEQ ID No.16: CGGTTGTTGCTGATCTGTCTCA;

[0069] Gene name: INHBA;

[0070] SEQ ID No.17: GTGCCCGAGCCATATAGCA;

[0071] SEQ ID No. 18: CGGTAGTGGTTGATGACTGTTGA.

[0072] In some embodiments, biomarkers are used to distinguish the risk of recurrence in patients with stage II and stage III colorectal cancer. In the risk assessment of stage II colorectal cancer, the biomarker is the cycle threshold difference ΔCt of IRS2-TRIM25, IRS2-MYBL2, KRT6B-FMNL2 and INHBA-MYC gene expression. For the risk assessment of stage III colorectal cancer, the biomarker is the cycle threshold difference ΔCt of IRS2-TRIM25, KRT6B-NAT1, FAP-MYC and INHBA-MYC.

[0073] In some embodiments, a set of biomarker combinations is used to distinguish the risk of recurrence in patients with colorectal cancer. The biomarker combination for colorectal cancer risk assessment may include at least the above biomarkers. In general, the biomarker combination may include any combination of all biomarkers, and generally, a smaller biomarker combination is sufficient to distinguish high-risk and low-risk patients with poor performance, but is more economical; however, a larger combination may provide more detailed information and can be applied to population groups in different regions.

[0074] Some embodiments disclose a method for calculating a recurrence score based on a binary scoring system, by performing RS scoring on a biomarker region to distinguish high-risk patients from low-risk patients. A low RS score indicates that the patient is unlikely to relapse, and a high RS score indicates that the patient is likely to relapse.

[0075] In some cases, clinical parameters are used in combination with the biomarkers described herein for colorectal cancer recurrence risk assessment. The present invention discloses methods for determining a patient's RS score and other clinical predictors of recurrence.

[0076] In some embodiments, the RS score of colorectal cancer is obtained by detecting the level of colorectal cancer biomarkers, wherein the RS score can be calculated by geometric mean, multivariate linear discriminant analysis or distributed gradient boosted decision tree machine learning, such as XGBoost, from the measured values ​​of biomarkers in the blood. In a binary model, the receiver operating characteristic ROC curve can be obtained by combining or pairing biomarkers. The RS score can be divided into a low-risk CRC recurrence clinical score or a high-risk CRC recurrence clinical score according to the method described herein.

[0077] In some embodiments, a method for risk assessment of colorectal cancer patients after initial remission of colorectal cancer patients is represented by the expression level of colorectal cancer biomarkers in the subject's tissue sample; for colorectal cancer risk assessment, the colorectal cancer RS ​​score is evaluated as high or low in two ranges to determine the risk of recurrence after initial treatment; if the colorectal cancer RS ​​score is higher than the RS critical value of 2.589, for example, it indicates that patients with stage II colorectal cancer are at high risk of poor prognosis of colorectal cancer after initial treatment; the critical value can be adjusted according to the population; if the colorectal cancer RS ​​score is higher than the critical value of -0.1355, it indicates that patients with stage III colorectal cancer have a higher risk of colorectal cancer recurrence; the critical value can be adjusted according to the population.

[0078] Some embodiments disclose a method for evaluating the prognosis / recurrence / relapse of a patient with colorectal cancer, comprising the following steps:

[0079] Obtain tumor samples from patients, including formaldehyde-fixed paraffin-embedded tissue, or FFPE tissue;

[0080] Measuring the level of each biomarker in the tumor sample, such as RNA / DNA copy number or concentration;

[0081] The level of each biomarker is compared to the value of the corresponding gene pair of the biomarker. Typically, the range of paired values ​​can represent the biomarker levels of one or more tumor samples from the same subject, or the biomarker levels of one or more tumor samples from one or more cancer patients, and the difference in the level of the combination of biomarkers in the biosamples compared to the reference value of the biomarker for a subject with a good prognosis indicates whether the patient is at high risk of recurrence.

[0082] In some embodiments, the method for evaluating the prognosis / recurrence / relapse of a colorectal cancer patient further comprises calculating a RS score to distinguish between high-risk and low-risk colorectal cancer patients.

[0083] Generally, the RS score of colorectal cancer can be obtained by the level of colorectal cancer biomarkers, and the RS score can be obtained by:

[0084] a. It can be obtained from the difference in cycle threshold C(t) between two different genes. For example, the biomarker group with Ct difference value is IRS2-TRIM25, IRS2-MYBL2, KRT6B-FMNL2, KRT6B-NAT1, FAP-MYC and INHBA-MYC.

[0085] can be derived from measured blood biomarker values ​​by geometric mean, multivariate linear discriminant analysis, or distributed gradient boosted decision tree machine learning; or,

[0086] c. It can be the fold difference of each pair of biomarkers, such as ΔC(t), concentration difference, or ΔMoM of Ct value, normalized to fit a range of values ​​with appropriate cutoff values ​​to distinguish high-risk and low-risk patients. For example, it can be derived from the stage II colorectal cancer formula (IRS2-TRIM25) + (IRS2-MYBL2) + (KRT6B-FMNL2) + (INHBA-MYC) and the stage III colorectal cancer formula (IRS2-TRIM25) + (KRT6B-NAT1) + (FAP-MYC) + (INHBA-MYC).

[0087] Typically, biomarkers can be measured using specific primers and reporter systems to determine biomarker and biomarker gene expression, such as gene copy number. Typically, methods for determining the copy number of biomarkers include, but are not limited to, quantitative PCR detection, reverse transcription quantitative PCR, gene microarray, RNA or DNA sequencing, sandwich analysis, magnetic capture, microsphere capture, electrophoretic blotting, surface enhanced Raman spectroscopy, flow cytometry or mass spectrometry.

[0088] In some embodiments, the copy number of the biomarker is determined by binding of specific DNA primers to the biomarker RNA, followed by reverse transcription and polymerase chain reaction, using a detectable reporter molecule; the reporter molecule is, for example, SYBR green dye.

[0089] Some embodiments disclose a kit for a quantitative qPCR system for measuring RNA / DNA biomarkers in a tumor sample. The kit may include a container for storing a biological sample collected and isolated from a human patient with stage II and stage III colorectal cancer. The kit contains at least one reagent for measuring a colorectal cancer risk biomarker, for reacting the reagent with the biological sample or a portion of the biological sample to measure at least one colorectal cancer biomarker in the biological sample. The reagents may be packaged in separate containers.

[0090] In some embodiments, the kit for a quantitative qPCR system further comprises one or more control reference samples and reagents for performing qPCR to detect the copy number of a biomarker as described herein.

[0091] In some embodiments, a quantitative qPCR system for detecting biomarkers using a kit includes:

[0092] Platform systems for measuring colorectal cancer biomarkers, such as the QuantStudio 4 system;

[0093] Calculation table for calculating colorectal cancer risk score;

[0094] Indicative criteria for determining patients' risk of recurrence and poor prognosis.

[0095] In some embodiments, in a kit for a quantitative qPCR system, the copy number of the biomarker expression level is expressed as a cycle threshold value C(t).

[0096] In some embodiments, the method for assessing the risk of recurrence in colorectal cancer patients by detecting biomarkers in tumor tissue comprises:

[0097] Collect primary tumor or FFPE tumor tissue samples from colorectal cancer patients and measure the copy number of each biomarker in the tumor tissue;

[0098] Comparing the measured values ​​of a panel of biomarkers in primary tumors or FFPE tumor tissues from patients with colorectal cancer with reference values ​​of the corresponding paired genes can assess the differential expression of these biomarkers in tissues;

[0099] Based on these differentially expressed data, the patient's colorectal cancer recurrence risk score, namely RS score, can be calculated, and the patient's recurrence risk can be further evaluated based on the RS score.

[0100] Typically, to measure at least one biomarker, specific primers are used to bind to the biomarker or a fragment thereof and the copy number of the biomarker is determined by PCR. These primers are designed based on the coding region (exon) sequence of the biomarker.

[0101] In some embodiments, specific primer pairs are selected that are capable of specifically binding to a series of specific biomarkers, such as IRS2, TRIM25, MYBL2, KRT6B, FMNL2, INHBA, MYC, NAT1 and FAP, etc., for accurate measurement and analysis.

[0102] In some embodiments, at least one pair of CRC biomarkers is measured, and the biomarkers are detected by oligonucleotide primers to calculate the RS score, wherein the primers specifically bind to the biomarkers or to biomarker fragments comprising RNA / DNA sequences of the biomarkers;

[0103] Primers are selected from partially complementary DNA sequences of the biomarker target;

[0104] Dye or dye / quencher reporter labels can accurately interpret the cycle threshold of a target biomarker, such as the amount of RNA or DNA in a sample;

[0105] qPCR instruments, such as qustudio4, obtain the Ct value of each biomarker based on the amplification results of the biomarker template, thereby determining the expression level of each biomarker.

[0106] Example 1

[0107] 1 Experimental methods

[0108] 1.1 Sample Information

[0109] Patient Cohort, Demographic Information, and Clinical Criteria for This Example 1

[0110] All study protocols for the validation cohort of colorectal cancer (CRC) patients, demographic information, and clinical criteria were approved by the Institutional Review Board (IRB) of Fudan University Cancer Hospital. Formaldehyde-fixed paraffin-embedded (FFPE) tissue samples were obtained from CRC patients with outcome information, which were categorized into high-risk and low-risk groups. In addition, CRC patients with normal mismatch repair (MMR) function were recruited for the study. FFPE primary cancer tissues were selected and characterized for analysis in Fudan University Cancer Hospital. For each patient, five unstained 5-μm sections were obtained. The patient cohort, demographic, and clinical information are shown in Table 1.

[0111] Table 1 List of patient cohorts, demographic and clinical information

[0112]

[0113] 1.2 Candidate marker selection

[0114] This Example 1 uses a meta-analysis of microarray datasets (GEO) to analyze differentially expressed genes associated with colorectal cancer outcomes and risks using training and validation machine learning algorithms. A total of six datasets were used, as listed in Table 2 below.

[0115] Table 2 Dataset list

[0116]

[0117] First, three datasets, GSE18105, GSE26906, and GSE4526, were used to reduce the number of gene features from 19,320 to 4,548;

[0118] Cox regression and LASSO regularization were used to stratify 4548 genes using the GSE17536 and GSE17537 datasets. Bagging (B=100) was used to improve LASSO regression.

[0119] The stratified genes were then retrained using GSE17536, GSE17537, and GSE17538, and twenty-nine genes were identified that were strongly associated with colorectal cancer recurrence risk and outcome. Twenty-two genes were validated to determine their ability to be amplified by q-PCR analysis in formaldehyde-fixed paraffin-embedded tissue (CRC FFPE), including six intestinal stem cell genes associated with recurrence risk; twelve Oncotype Dx genes were then also included in the discovery panel as controls, and a total of forty genes were included in the qPCR validation panel. Forty genes were IRS2, TRIM25, MET, GSTM3, KRT6B, PKIB, VLDLR, ADAMTS5, ANAPC5, DPT, FAM111A, NADKD1, NAT1, WNT5A, FOXN3, CCL20, KLK6, DCBLD2, PKIG, DCTN5, SAMHD1, C5orf4, BGN, FAP, INHBA, Mki67, MYC, MYBL2, GADD45B, ATP5E, GPX1, PGK1, VDAC2, UBB, BCL2, FNML2, IGFBP4, SLCO3A1, CXCR4, and VEGFA.

[0120] Sample RNA extraction and qPCR detection

[0121] Extract mRNA from formaldehyde-fixed paraffin-embedded tissues and perform real-time fluorescence quantitative PCR detection. Treat colorectal cancer FFPE tissue sections with mismatch repair function with dewaxing solution. Use Deparaffinization Solution (Qiagen, 19093) and RNeasy_FFPE Kit (Qiagen, 73504) to treat formaldehyde-fixed paraffin-embedded tissues to preserve mRNA useful for subsequent qPCR analysis. Use specific primers for 40 genes to convert mRNA into cDNA. Then, pre-amplify the cDNA for 15 cycles, and dilute the product to 1:5 for qPCR detection and analysis.

[0122] In some embodiments, the qPCR system is as shown in Table 3 below.

[0123] Table 3 qPCR system composition list

[0124]

[0125] The qPCR amplification reaction procedure is shown in Table 4.

[0126] Table 4 qPCR amplification reaction procedure

[0127]

[0128] 1.4 Statistical analysis

[0129] All statistical analyses were performed using R software (version 4.1.2), including the Bioconductor package (version 3.5) and the R-Studio package (version 2022.02.0). All tests were two-sided log-rank tests; P values ​​< 0.05 and univariate hazard ratios > 2 were considered statistically significant.

[0130] Forty genes were paired with reference genes and normalized using the difference in Ct values ​​between each up-regulated and down-regulated gene. An exhaustive search was performed on the summed combinations of all gene pairs to determine the optimal gene pair panel by testing the hypothesis that the proportion of relapse-free patients would be significantly higher in the low expression difference group than in the high expression difference group for both stage II and stage III patient cohorts. The optimal cutoff point on the ROC curve was determined by comparing the panel RS scores of relapsed and non-relapsed patients in the stage II and stage III patient cohorts using the Youden index. The three-year recurrence of surgery-only patients was evaluated by the Kaplan-Meier estimation method based on the high-risk and low-risk groups defined according to the optimal cutoff panel score.

[0131] result

[0132] 2.1 Patient demographics and characteristics:

[0133] This Example 1 focuses on 95 patients with stage II and stage III colorectal cancer with mismatch repair function. Among them, there are 45 recurrent and 50 non-recurrent colorectal cancer patients. For stage II colorectal cancer, there are 20 recurrent and 25 non-recurrent patients. For stage III colorectal cancer, there are 25 recurrent and 25 non-recurrent patients. The demographic information and clinical characteristics of the patients are described in Table 1, and there are no significant differences.

[0134] Differentially expressed genes associated with CRC risk assessment

[0135] Differentially expressed genes associated with CRC risk assessment were identified from the microarray dataset analysis and the formaldehyde-fixed paraffin-embedded validation panel. A total of 29 genes were identified from the microarray dataset meta-analysis, which were ADAMTS5, ANAPC5, C5orf4, CCL20, CRNDE, DCBLD2, DNER, DPT, FAM111A, GSTM3, IRS2, KLK6, KRT6B, MET, NADKD1, NAT1, NMU, NOB1, PKIB, PKIG, PTPLA, TPBG, TRIM25, VLDLR, WNT5A, ZFYVE27, DCTN5, FOXN3, and SAMHD1.

[0136] These 29 genes were tested for their ability to be detected in formaldehyde-fixed paraffin-embedded tissues of colorectal cancer, and 22 of them were found to have detectable levels and were included in the panel. Six additional intestinal stem cell genes associated with colorectal cancer recurrence, as well as Oncotype Dx genes included as controls, resulted in a final gene panel consisting of IRS2, TRIM25, MET, GSTM3, KRT6B, PKIB, VLDLR, ADAMTS5, ANAPC5, DPT, FAM111A, NADKD1, NAT1, WNT5A, FOXN3, CCL20, KLK6, DCBLD2, PKIG, DCTN5, SAMHD1, C5orf4, BGN, FAP, INHBA, Mki67, MYC, MYBL2, GADD45B, ATP5E, GPX1, PGK1, VDAC2, UBB, BCL2, FNML2, IGFBP4, SLCO3A1, CXCR4, and VEGFA. The expression of these genes in each FFPE sample was evaluated individually, and all expression data are presented as C(t) values ​​expressed in FFPE tissues.

[0137] Furthermore, biomarkers that can predict the prognosis and clinical outcomes of colorectal cancer, such as IRS2, TRIM25, MYBL2, KRT6B, FMNL2, INHBA, MYC, NAT1 and FAP, were selected for precise measurement and analysis.

[0138] The relationship between the two internal reference genes and the genes was used for univariate analysis, and the p-value, AUC (area under the curve), and hazard ratio (HR) of the ΔCt value of the paired genes were calculated to screen out gene pairs that can distinguish between recurrence and non-recurrence. The selection criteria are shown in Table 5.

[0139] Table 5 Selection criteria for univariate analysis

[0140]

[0141] Finally, 15 gene pairs were determined to meet the above criteria, see Table 6 below.

[0142] Table 6 List of univariate analysis selection results

[0143]

[0144] Based on the above 15 gene pairs, all possible combinations were calculated, and the biomarker combination with the highest risk ratio was finally selected in the stage II and stage III patient cohorts (see Table 7).

[0145] Table 7 Biomarker combinations with the highest hazard ratios in phase II and phase III cohorts

[0146]

[0147] 2.3 Construction and validation of risk assessment / recurrence panels for stage II and III colorectal cancer

[0148] Markers were paired based on differences in gene expression as biomarkers for predicting colorectal cancer risk and exhaustively searched to maximize the risk prediction value.

[0149] For stage II colorectal cancer, based on the Youden index of 2.589 as the reference value, the gene expression difference combination:

[0150] (IRS2-TRIM25)+(IRS2-MYBL2)+(KRT6B-FNML2)+(INHBA-MYC)

[0151] The above CRC risk assessment formula can make the most effective prediction of the risk of recurrence of stage II colorectal cancer. As shown in Table 8, the predicted hazard ratio (HR) for stage II colorectal cancer is 2.5.

[0152] For stage III colorectal cancer, based on the Youden index of -0.1356 as the reference value, the gene expression difference combination is:

[0153] (IRS2-TRIM25)+(KRT6B-NAT1)+(FAP-MYC)+(INHBA-MYC)

[0154] The above CRC risk assessment formula can make the most effective prediction of the risk of colorectal cancer recurrence. As shown in Table 8, the predicted risk ratio for stage III colorectal cancer recurrence is 4.2.

[0155] If the Oncotype Dx combination in the prior art is used, the hazard ratio (HR) of stage II and stage III colorectal cancer obtained from the qPCR data of Example 1 of the present invention is 1.6.

[0156] Table 8 Recurrence combination performance of mProbe and Oncotype Dx

[0157]

[0158] In Table 8, the mProbe II stage gene combination is IRS2-TRIM25, IRS2-MYBL2, KRT6B-FMNL2, INHBA-MYC; the mProbe III stage gene combination is IRS2-TRIM25, KRT6B-NAT1, FAP-MYC, INHBA-MYC; the OncotypeDx gene combination is FAP, GADD45B, MKi67, MYBL2, MYC, BGN, INHBA; the internal reference genes are GPX1, PGK1, UBB, ATP5E, and VDAC2.

[0159] Figure 1 to Figure 3 The three-year recurrence rate for patients undergoing surgery alone was estimated by Kaplan-Meier, and the recurrence of patients with colon cancer was observed according to the risk groups classified by mProbe RS score, among which, Figure 1 For the entire cohort of patients, Figure 2 For patients in stage II, Figure 3 Patients with stage III disease;

[0160] Figures 4 to 6 is the recurrence-free interval of the mProbe recurrence score (RS) group, where Figure 4 For all patients, Figure 5 For patients in stage II, Figure 6 Patients with stage IIIA / B disease;

[0161] Figure 7 to Figure 9 The three-year recurrence rates for the risk groups of patients undergoing surgery alone were estimated by Kaplan-Meier using Oncotype Dx and the scoring system, where Figure 7 For the entire cohort of patients, Figure 8 For patients in stage II, Fig. 9 Patients with stage III colon cancer.

[0162] Figure 10 to Figure 12 is the recurrence-free interval according to the Oncotype Dx Recurrence Score (RS) group, where Fig.10 For all patients, Fig.11 For patients in stage II, Fig.12 The patients are stage IIIA / B patients.

[0163] Colorectal cancer patients were classified according to the colorectal cancer gene combination and RS scoring system in stage II and stage III, and the corresponding reference values ​​of colorectal cancer patients were set as 2.589 and -0.1356. Figure 1 and Figure 2 As shown, qPCR analysis based on gene expression differences of paired genes, followed by the RS scoring system, was able to accurately predict and distinguish between high and low risk groups of three-year recurrence in surgery-only patients.

[0164] Parallel analyses were performed using the Oncotype Dx combination and formula as controls, e.g. Figure 3 and Figure 4 The results showed that the hazard ratio (HR) was similar to that of Oncotype Dx, and the hazard ratio (HR) was about 1.38, while the hazard ratio observed in Example 1 was 1.6. The data showed that the performance of the panel and RS model for colorectal cancer risk assessment and recurrence in Example 1 was far superior to the Oncotype Dx combination and model in the prior art.

[0165] The embodiments of the present invention disclose a biomarker group, a primer group, and a detection kit for predicting the clinical outcomes of the prognosis of stage II and stage III colorectal cancer. By detecting the levels of colorectal cancer biomarkers, a colorectal cancer RS ​​score can be obtained, which can effectively distinguish the high and low risks of colorectal cancer recurrence; it can better evaluate the treatment risk and prognosis of colorectal cancer patients, thereby providing patients with more personalized and effective treatment plans.

[0166] The technical solutions disclosed in the embodiments of the present invention and the technical details disclosed in the embodiments are merely illustrative of the inventive concept of the present invention and do not constitute a limitation on the technical solutions of the embodiments of the present invention. Any conventional changes, replacements or combinations of the technical details disclosed in the embodiments of the present invention have the same inventive concept as the present invention and are within the protection scope of the claims of the present invention.

Claims

1. A biomarker for predicting clinical outcome of stage II and stage III colorectal cancer prognosis, characterized in that: The biomarker for recurrence risk assessment in patients with stage II colorectal cancer is a combination of the gene pairs IRS2-TRIM25, IRS2-MYBL2, KRT6B-FMNL2, and INHBA-MYC; The biomarker used for recurrence risk assessment in patients with stage III colorectal cancer is a combination of the gene pairs IRS2-TRIM25, KRT6B-NAT1, FAP-MYC, and INHBA-MYC.

2. Use of a primer set for PCR detection of the expression level of the biomarker according to claim 1 in the preparation of a detection kit for predicting the prognosis clinical results of stage II and stage III colorectal cancer, characterized in that: The primer set consists of an IRS2 primer set, a TRIM25 primer set, a KRT6B primer set, a MYBL2 primer set, a FMNL2 primer set, a NAT1 primer set, a FAP primer set, a MYC primer set, and an INHBA primer set, and the sequences of the primer sets are listed in SEQ ID No. 1 to 18, respectively.

3. The use according to claim 2, characterized in that: The formula used to estimate the risk of recurrence in patients with stage II colorectal cancer is: (IRS2-TRIM25)+(IRS2-MYBL2)+(KRT6B-FMNL2)+(INHBA-MYC); If the score is higher than the cut-off value of 2.589, it indicates that patients with stage II colorectal cancer are at high risk of poor prognosis after initial treatment; The formula used to estimate the risk of recurrence in patients with stage III colorectal cancer is: (IRS2-TRIM25)+(KRT6B-NAT1)+(FAP-MYC)+(INHBA-MYC); If the score is higher than the critical value of -0.1356, it indicates that patients with stage III colorectal cancer have a higher risk of colorectal cancer recurrence; Among them, IRS2-TRIM25, IRS2-MYBL2, KRT6B-FMNL2, INHBA-MYC, KRT6B-NAT1, and FAP-MYC represent the cycle threshold difference ΔCt of the genes.